Live-Attenuated Hepatitis A Vaccine, Freeze-Dried
The first viral vaccine which holds the independent intellectual property in China.
The National Torch Program’, ‘The National Major New Products’.
Over 200 million doses have been provided.
The market share in China ranks among the top.
The Representative Research and Production Base for Series of Hepatitis A Vaccines in China
As early as in 1974, IMBCAMS independently established a human diploid cell line, KMB17. Its establishment provides a base for the subsequent development of new vaccines from human diploid cells.
In 1992, the live-attenuated Hepatitis A vaccine (liquid) from IMBCAMS was firstly permitted to market.
The inactivated Hepatitis A vaccine, WEISAIRUIAN®, and the freeze-dried live-attenuated Hepatitis A vaccine, WEISAIRUIJI®, were respectively put into Chinese market in 2003 and 2006.
A Manufacturer Who Remarkably Contributes to Prevent Hepatitis A in China
The Hepatitis A vaccine has been included into the Expanded Program on Immunization (EPI) in 2007.
For more than 20 years, IMBCAMS provided Chinese market about 200 million doses of Hepatitis A vaccines in total.
Main Active Composition:
Live-attenuated Hepatitis A virus.
Adjuvants: Gelatin, Mycose, Glycine, Dextranum.
Vaccine Diluent: Sterile water for injection.
Description: Milky white loose body, becoming clear liquid after dissolving.
Storage: Stored and transported in 2-8℃, protected from light.
Period of Validity: 18 months.
The vaccine can induce immunity against Hepatitis A virus to prevent hepatitis A.
Hepatitis A vulnerable population over 18 month age.
Administration and Dosage:
Before usage, add the instructed amount of vaccine diluent into the vial containing vaccine powder, shake well to ensure the powder is totally dissolved. Subcutaneous injection in the lateral deltoid of the upper arm is recommended for this vaccine. 1.0 ml per person, and only one dose is required.
- Coming Soon...